Clinical trials
Advanced Tumors clinical trials
Below are recruiting advanced tumors clinical trials, each written for real people, not researchers. We’re tracking 1,346 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07182591RecruitingPhase 1
Study of DS5361b for advanced solid tumors with high TMB or MSI
This study tests a new drug (DS5361b) for people with advanced solid tumors that have high genetic instability (TMB-H or MSI-H). It aims to see if the drug can shrink tumors or slow their growth.
Sarasota, FloridaAges 18 years+ - NCT07131202RecruitingPhase 1/Phase 2
FL115 plus PD-1 antibody for advanced solid tumors
This trial tests a new drug called FL115 combined with an immunotherapy (PD-1 antibody) for people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if this combination can shrink tumors or slow their growth.
Guangzhou, GuangdongAges 18–80 - NCT05877664RecruitingPhase 1
Test drug ZG0895.HCl in advanced solid tumors
This Phase 1 trial studies ZG0895.HCl, a new experimental treatment, in people with advanced solid cancers. It’s mainly to check safety and how the body responds, and it may help by shrinking or controlling tumors if the drug works.
Zhejiang, HangzhouAges 18–75 - NCT07359066RecruitingPhase 1/Phase 2
SPR1020 for advanced solid tumors with DNA repair defects
This trial tests an experimental drug (SPR1020) for people with advanced solid tumors that have not responded to standard treatments, especially those with BRCA or related gene mutations. The drug is taken by mouth and the study aims to find the right dose and see if it helps shrink tumors.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06233942RecruitingPhase 1
Testing a new drug for advanced solid tumors
This early-phase trial tests a new drug called BG-C9074, either alone or with other cancer treatments, for people with certain advanced solid tumors that have not responded to standard therapy. The goal is to see if it is safe and effective.
Los Angeles, CaliforniaAges 18 years+ - NCT07356453RecruitingPhase 1
Study of PARG inhibitor FORX-428 for advanced solid tumors
This trial tests a new drug called FORX-428, which targets a protein called PARG, in people with advanced solid tumors. It is for patients whose cancer has not responded to prior treatments and who have specific genetic changes, such as BRCA mutations.
Palo Alto, CaliforniaAges 18 years+ - NCT06352359RecruitingPhase 1
Study of ONC 841 for advanced solid tumors
This phase 1 study tests an experimental drug called ONC 841 for people with advanced solid tumors that have not responded to other treatments. The trial aims to find a safe dose and see if the drug can shrink tumors.
Sacramento, CaliforniaAges 18 years+ - NCT04855656RecruitingPhase 1
Lunresertib for advanced solid tumors with specific gene changes
This early-phase trial tests lunresertib alone or with other study drugs in people with advanced solid tumors that have certain tumor gene changes. It aims to see whether the treatment is safe and whether it can help shrink or control cancer.
Los Angeles, CaliforniaAges 12 years+ - NCT05687682RecruitingPhase 1
AM-928 infusion safety study for advanced solid tumors
This Phase 1 trial tests how safe AM-928 is when given through an IV infusion to people with advanced solid cancers that can’t be removed by surgery and have stopped responding to standard treatments. It may help doctors learn the safest dose and whether the drug causes side effects worth watching.
TaipeiAges 18 years+ - NCT06487455RecruitingPhase 1
SPH7485 tablets for advanced solid tumors
This phase 1 trial tests a new oral drug called SPH7485 for people with advanced solid tumors that have not responded to other treatments. The goal is to see if the drug is safe and effective.
ChangshaAges 18–75 - NCT06954558RecruitingPhase 1
GK01 for advanced solid tumors that are hard to treat
This trial tests a new drug called GK01 in patients with advanced solid tumors that have stopped responding to standard treatments. It aims to see if the drug is safe and effective, and may be an option for those who can have a tumor surgically removed.
TianjinAges 18–70 - NCT05868876RecruitingPhase 1
Testing AK127 plus AK104 for advanced cancers
This Phase 1 study tests the safety and early anti-cancer activity of AK127 given together with AK104 in people with advanced solid tumors. You may be considered if standard treatments have already been tried or aren’t suitable for you.
Tianjin, Tianjin MunicipalityAges 18–75 - NCT06795412RecruitingPhase 1/Phase 2
PYX-201 plus pembrolizumab for advanced solid tumors
This trial tests a new drug called PYX-201 combined with an immunotherapy (pembrolizumab) for people with advanced solid tumors that have not responded to standard treatments. The goal is to see if this combination can shrink tumors and help people live longer with manageable side effects.
San Diego, CaliforniaAges 18 years+ - NCT06329206RecruitingPhase 1
GH2616 tablet for advanced solid tumors
This trial tests an experimental tablet, GH2616, for people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if the drug is safe and effective.
ZhejiangAges 18 years+ - NCT06801470RecruitingPhase 1
Testing the safety of CD-001 in advanced solid tumors
This early-phase trial tests a new drug (CD-001) for people with advanced solid tumors. It will check if the drug is safe, how the body handles it, and if it helps shrink tumors.
TianjinAges 18 years+ - NCT07163325RecruitingPhase 1
Testing a new drug for advanced solid tumors
This trial tests a new oral drug called EP102 for people with certain advanced cancers that have stopped responding to standard treatments. It aims to see if the drug is safe and works by targeting a protein called METTL3.
BrusselsAges 18 years+ - NCT06804824RecruitingPhase 1
Testing a new drug for advanced solid tumors with certain gene changes
This study tests an experimental drug called VVD-159642 in people with advanced solid tumors that have specific genetic changes (RAS or EGFR alterations, or HER2 overexpression). The goal is to see if the drug is safe and tolerable.
Grand Rapids, MichiganAges 18 years+ - NCT06589596RecruitingPhase 1
Study of BGB-58067 for advanced solid tumors
This trial tests an experimental drug called BGB-58067, either alone or with other cancer treatments, for people with advanced solid tumors that have stopped responding to standard therapy. It may be an option if you have a specific genetic change (loss of MTAP) in your tumor.
Los Angeles, CaliforniaAges 18 years+ - NCT06514651RecruitingPhase 1
MAQ-001 for advanced solid tumors after PD-1/PD-L1 therapy
This study tests a new experimental drug called MAQ-001 in people with advanced solid tumors or lymphomas that have already been treated with a PD-1/PD-L1 checkpoint inhibitor. The goal is to see if MAQ-001 can shrink or control the cancer when other treatments are no longer working.
LyonAges 18 years+ - NCT06929663RecruitingPhase 1
Study of AK146D1 for advanced solid tumors
This study tests an experimental drug (AK146D1) for people with advanced solid tumors that are no longer responding to standard treatments. The goal is to see if it is safe and effective.
Sydney, New South WalesAges 18–75 - NCT07256782RecruitingPhase 1/Phase 2
A study of QLC5508 combinations for advanced solid tumors
This trial tests a new drug called QLC5508, given in combination with other treatments, for people with advanced solid tumors that have stopped responding to standard therapy or who haven't had treatment yet. The goal is to see if the combination can shrink tumors or slow their growth.
ShanghaiAges 18 years+ - NCT05684965RecruitingPhase 1/Phase 2
Study drug for advanced solid cancers after standard treatments
This Phase 1/2 trial tests XTX301, a study treatment, in people with advanced solid tumors (cancers) that have already been treated and are not controlled by standard options. It may help if your cancer matches one of the study groups and you meet safety and test-tissue requirements.
Sacramento, CaliforniaAges 18 years+ - NCT06764836RecruitingPhase 1
IMM2510 + IMM27M for advanced solid tumors
This study tests a combination of two immune-based drugs, IMM2510 and IMM27M, for people with advanced solid tumors that have not responded to standard treatments. The goal is to see if this combination can shrink or slow the growth of cancer.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT05765851RecruitingPhase 1
HER2-targeting drug study for advanced solid tumors
This Phase 1 trial tests a combination of medicines (including DS-1103a) for people with advanced, hard-to-remove (unresectable) or metastatic solid tumors that have HER2 changes. Because it’s an early safety/dose study, it mainly aims to find the right dose and see how the tumor responds.
Sarasota, FloridaAges 18 years+
Hear when a new Advanced Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for advanced tumors?
- Yes. Clin2 currently lists 1,346 recruiting advanced tumors studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a advanced tumors trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a advanced tumors trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Advanced or Metastatic Solid Tumors
- Locally Advanced or Metastatic Solid Tumors
- Advanced Malignant Tumors
- Advanced/Metastatic Solid Tumors
- Locally Advanced (Unresectable) or Metastatic Solid Tumors
- Patients With Advanced Solid Tumors
- Locally Advanced/Metastatic Solid Tumors
- Mesothelin-positive Advanced Malignant Solid Tumors
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.